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ABSTRACT
Free light chains (FLCs) are tumour markers of monoclonal gammopathies. Detection of urinary FLC or also known 
as Bence-Jones protein through urinary protein and its immunofixation electrophoreses (UPE and uIFE, respectively) 
have been considered the gold standard for its biochemical diagnosis. This is mainly due to their superior detection 
limits compared to their counterpart investigations in serum. However, urinalysis is limited in many ways. The 
emergence of serum FLC assay with markedly improved detection limit circumvents many of these problems and 
has gained much importance in biochemical investigations of monoclonal gammopathies. Nevertheless, they are not 
without limitations. This review discusses the advantages and limitations of serum and urinary FLC assays.
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Free light chains (FLCs) are tumour markers of monoclonal 
gammopathies, particularly of those secreting light 
chains. Its biochemical detection in serum and urine is 
of paramount importance in diagnosing and monitoring 
these disorders. Traditionally, screening of monoclonal 
gammopathies relies on serum and urine protein 
electrophoreses, with the latter long being considered 
as its ‘gold standard’ test (1). However, these methods 
have limitations in detecting FLC, many of which have 
been overcome by a newer assay of serum FLC. This 
brief review aims to critically discuss FLC assays, from 
conventional to current. 
LIGHT CHAIN IMMUNOGLOBULINS
Immunoglobulins are products of plasma cells comprising 
of heavy and light chains. The latter may either be bound 
to a heavy chain in an intact immunoglobulin, or exists 
as free light chains. The two types of light chains, kappa 
(κ) and lambda (λ) are structurally heterogenous, with κ 
being predominantly monomeric and λ dimeric (2). In 
addition, higher polymeric forms as well as fragments 
of both types of FLCs may also exist (2). Serum FLC 
concentrations depend upon the balance between 
production and renal clearance (2). They are rapidly 
cleared through the glomeruli before being reabsorbed 
and catabolised in the proximal tubules (2). Normally 
little protein is present in the urine due to the huge 
tubular reabsorptive capacity (2).
Urinary FLC, also known as Bence-Jones protein (BJP), 
thus represents an overflow proteinuria that occurs 
when an overproduction of FLCs overwhelms renal 
tubular reabsorptive capacity (2). First discovered by an 
English physician, Dr. MacIntyre in 1845 as a urinary 
protein in an oedematous patient, it was sent to Dr. 
Bence Jones, a chemical pathologist, for identification 
(2). Dr. Bence Jones subsequently published the findings 
of the peculiar protein, which he described as ‘hydrated 
deutoxide of albumen’ in 1847 and hence the eponym 
(2,3). However, it was not until 1962 that the identity of 
BJP was established as monoclonal FLC (2,4).  
MONOCLONAL GAMMOPATHIES 
Monoclonal gammopathies are characterised by 
proliferation of one or more neoplastic clones of 
plasma cells, which usually secrete monoclonal 
immunoglobulins or M-proteins (5). Clinically, they 
encompass a broad spectrum of diseases ranging from 
premalignant disorders of monoclonal gammopathy 
of undetermined significance (MGUS) and smoldering 
multiple myeloma, to malignant disorders of multiple 
Mal J Med Health Sci 13(2): 59-62, June 201760
Malaysian Journal of Medicine and Health Sciences (ISSN 1675-8544)
myeloma (MM) (6). The M-protein may consist of an 
intact immunoglobulin, the light chain only, or the 
heavy chain only (5). Not only M-proteins vary in 
structure, their concentrations also widely vary. Up to 
3% of patients with MM are designated as non-secretory 
MM with no detectable M-protein in serum or urine 
(7). On the other hand, oligosecretory MM secrete 
small amounts of M-protein of less than 10 g/L and 
200 mg/24h, in the serum and urine, respectively (8,9). 
Such diseases include light chain multiple myeloma 
(LCMM), and related low tumour-burden disorders. The 
latter is defined as a small clonal proliferation of plasma 
cells producing toxic M-protein leading to end-organ 
damage, as seen in amyloid light chain (AL) amyloidosis 
and light chain deposition disease (LCDD) (10,11). 
SERUM PROTEIN ELECTROPHORESIS AND 
IMMUNOFIXATION
Biochemically, serum protein electrophoresis 
(SPE) is the standard screening test for monoclonal 
gammopathies (2). M-proteins migrate as discrete 
bands on an electrophoretic gel, such as agarose 
gel, whilst a densitometric peak provides a semi-
quantitative value for its concentration (1). Subsequent 
serum protein immunofixation electrophoresis (sIFE) 
confirms its clonality. In the absence of reactivity for 
immunoglobulin (Ig) G, A or M, presence of IgD and 
IgE monoclonals must be excluded before a diagnosis 
of monoclonal light chain is made (5,8). The detection 
limit of SPE ranges from 500-2000 mg/L, whilst that of 
sIFE is 10-fold lower (50-200 mg/L) (2,12). However, in 
non- or oligosecretory disorders, serum FLC levels may 
be missed on SPE and sIFE as their concentrations are 
well below the detection limits of these assays (1).
URINE PROTEIN ELECTROPHORESIS AND 
IMMUNOFIXATION
Since it can be concentrated many times, urine protein 
electrophoresis (UPE) and its immunofixation (uIFE) are 
much more sensitive than those of serum, with detection 
limits of 10-40 mg/L and has been traditionally recognised 
as the gold standard for detection of urinary FLCs (1,5). 
However, technical issues include cumbersome and 
inaccurate 24-hour urine collection (1). In recent years, 
it has been recommended to validate the accuracy of 
urine collection against creatinine clearance (13). Kaplan 
& Horowitz 2011 (13) also suggested the possibility 
of using the BJP to creatinine ratio from random urine 
samples to determine 24-hour BJP excretion. 
Measurement of urinary total protein is part of BJP 
quantitation, which is important in disease definitions 
and staging (14). However, methods of both precipitating 
and dye-binding, are often insensitive to microproteins 
in general and to FLC fragments in particular (14). 
Also, proteins differ in their affinities for the dyes used, 
leading to non-linear densitometric response, giving rise 
to over- or underestimation of BJP concentration (14). 
Furthermore, urine concentration can be technically 
demanding with the existence of different practices (4). 
Overconcentration of urine, however, may form ‘ladder 
banding’ pattern, giving a false impression of monoclonal 
bands (4). Meanwhile, increased urinary polyclonal 
FLCs, as seen in systemic lupus erythematosus, increases 
non-specific background staining, thus obscuring any 
monoclonal light chain, giving rise to false negative 
results (5). In addition, batch analysis of urine samples 
may lead to delayed results (1). Although uIFE offers 
higher analytical sensitivity than UPE, it is a non-
quantitative assay and is prone to antigen excess due to 
a wide range of urinary FLC concentrations, which may 
cause falsely negative findings (1,4). 
Nevertheless, the underlying renal pathology may 
be inferred to a certain extent from the degree and 
pattern of proteinuria seen on densitometry and UPE, 
respectively. For instance, glomerular proteinuria, 
indicative of an underlying glomerular damage such 
as glomerulonephritis typically presents as gross 
proteinuria of >3.5 g/day and an albuminuric pattern on 
UPE (4,9). Tubular damage, such as Fanconi syndrome, 
is suggestive by proteinuria of 1-3 g/day and a more 
generalised pattern of proteinuria on UPE (4,9).  
SERUM FREE LIGHT CHAIN ASSAY
More than a decade ago, an interest in measuring FLC 
in the serum had emerged.  The assay has since been 
internationally recommended as part of the screening 
panel for monoclonal gammopathies, with some 
exception, replacing urinary FLC analysis (7). This assay 
has been a major shift from the previous serum total 
light chain assays, which measure both bound and free 
light chain (1). Serum FLC assays are immunoassays, 
utilising antibody recognition of epitopes on the FLC 
constant region, which are otherwise hidden in an 
intact immunoglobulin (1,2,15). Being a serum assay, it 
negates urinalysis.  With analytical sensitivity of 1.5 and 
3.0 mg/L for kappa (κ) and lambda (λ) FLC, respectively, 
the assay is particularly useful in non- and oligosecretory 
disorders, which are often undetected by SPE or IFE 
(1,15). Calculation of κ: λ ratio confirms clonality, 
whereby monoclonal expansion of a single type of FLC 
gives an abnormal ratio (1,2).  In contrast, a polyclonal 
production of FLCs, as seen in infection, increases both 
types of FLCs and thus a normal ratio. Although κ is 
produced twice as much as λ, being monomeric, the 
former is cleared much faster, resulting in the normal 
serum κ: λ ratio of around 0.55 (0.26- 1.65) and both 
having short half-lives of 2-3 h and 5-6 h for κ and λ, 
respectively (2,12).  
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IS SERUM FLC A BETTER TEST?
The arguments in favour of serum FLC measurement are 
as follow. Physiologically, FLCs are freely filtered at the 
glomerulus and reabsorbed before being catabolised in 
the proximal tubules. However, tubular reabsorptive 
capacity ranges widely, reaching up to 10–30g of FLC 
daily, which is way beyond the normal plasma cell 
production of 0.5–1 g per day (6). The median serum 
FLCs required to produce overflow proteinuria have 
been measured at 113mg/L and 278 mg/L for κ and 
λ, respectively (6). Thus, the amount of urinary FLCs 
is therefore heavily dependent upon renal function. 
Not only measurement of urinary FLCs may miss 
oligosecretory but more importantly, it is not reflective 
of FLC production rate and thus potentially becoming 
unreliable for diagnosis in both early stages and 
advanced light-chain myeloma (12). Secondly, the short 
half-lives of serum FLC allow “real-time” assessment 
of response to therapy, which is also advantageous 
in patients with intact immunoglobulin MM (15). 
Monitoring of the latter by SPE would be less accurate 
due to longer half-lives of intact immunoglobulins (1). 
Similarly, assessment of response by UPE may miss low 
levels of BJP in oligosecretory disorders. Thirdly, as FLCs 
are produced in excess of heavy chains to ensure proper 
conformation of intact immunoglobulins, therefore, an 
increase in serum FLC concentrations may be detected 
the earliest during relapse (12,15). Patients with intact 
immunoglobulin MM have been shown to relapse with 
monoclonal FLCs only, a phenomenon termed ‘light 
chain escape’, which may otherwise be missed on SPE 
or UPE (1). 
Definition of myeloma kidney has traditionally been 
based on merely a fixed level of serum creatinine of 173 
µmol/L and later by serum creatinine-based estimated 
glomerular filtration rate equations (7). Recently, the 
international guideline has incorporated serum FLC 
in redefining myeloma kidney as part of its clinical 
features (7). Patients with myeloma kidney typically 
have baseline serum FLC concentrations exceeding 
500 mg/L (1). The guideline now regards serum FLC of 
>1500 mg/L, which is presumptive of light chain-cast 
nephropathy, as myeloma-defining event (10). The 
invasive but definitive renal biopsy is recommended to 
clarify the underlying cast nephropathy particularly if 
serum FLC is less than 500 mg/L (7). 
LIMITATIONS OF SERUM FLC ASSAY
The first generation assay, the Freelite assay (Binding Site 
Ltd., UK) utilises polyclonal antibodies that recognise 
a wide range of epitopes on the FLCs multimers (1). 
Much work, including the international guideline has 
been based on this assay (1,12). However, each FLC is 
unique with its own set of epitopes, and therefore may 
not react appropriately with the polyclonal antibodies 
in the calibrator. Thus, equimolar reactivity of the 
polyclonal antibodies against FLC multimers, ranging 
from monomeric κ to dimeric λ as well as higher 
polymers, is questionable.  In addition, the epitope 
recognised by the antibody varies only slightly from that 
on an intact immunoglobulin, giving rise to a potential 
cross-reactivity (11). The second generation, the N Latex 
assay (Siemens Healthcare Diagnostics, Germany) uses 
monoclonal antibodies recognising a specific epitope 
on a specific form of FLC, therefore having an increased 
specificity (1). However, due to its monoclonal nature, 
the calibrator in this assay has a limited coverage of 
the FLC multimers (1). Furthermore, being recently 
introduced, this assay is less widely validated compared 
to the first generation and only available on a single 
platform (12). Recently, a third generation assay based 
on monoclonal antibody is emerging, which, unlike the 
previous assays, offers simultaneous measurement of 
both κ and λ FLCs (16). Likewise, this assay has yet to be 
widely validated.
In addition, there are several other analytical issues 
impacting the sFLC assays. Currently, neither assay 
(Freelite or N Latex assay) is able to fulfill the desirable 
imprecision targets (17).  Both assays are also subject 
to non-linearity of FLC during immunoassay reaction, 
resulting in underestimation of FLC concentration and 
non-specific interferences, causing both falsely high and 
low FLC concentrations (17). Variation seen in different 
batches of antisera affects both types of assays, but being 
monoclonal, it is less of a problem for the N Latex assay, 
giving rise to inaccuracy problem (17). Furthermore, 
both are also affected by antigen excess as FLC levels 
widely range from 1-100,000 mg/L, leading to falsely 
low results (17). 
The major analytical issue is accuracy (12,17). Due 
to its heterogeneity, the true definition of serum FLC, 
the measurand, remains elusive and hampers reliable 
recognition of all its molecular forms equivocally, 
as discussed earlier (9). Thus, until today, there is no 
international reference material or method for serum 
FLC (9). Hence, a uniform calibration traceability is yet 
to be achieved. Clinically, lack of harmonisation and 
standardisation raises important issues such as whether 
a patient meeting certain criteria is very much assay-
dependent (9,13). It hinders assay interchangeability 
(9,12). Therefore, in following up and monitoring of 
patients, one should use the same serum FLC assay, 
platform and laboratory, as both within and between-
assay variations have been observed (9,12,17). 
CONCLUSIONS
In conclusion, although serum FLC assay, with its 
improved analytical sensitivity, has been integrated into 
monoclonal gammopathies work up, one should bear in 
mind its limitations. Alternatively, limited yet sufficient 
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clinical information is still inferable from the older 
conventional tests, such as UPE.  
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